UY32494A - Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones - Google Patents

Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones

Info

Publication number
UY32494A
UY32494A UY0001032494A UY32494A UY32494A UY 32494 A UY32494 A UY 32494A UY 0001032494 A UY0001032494 A UY 0001032494A UY 32494 A UY32494 A UY 32494A UY 32494 A UY32494 A UY 32494A
Authority
UY
Uruguay
Prior art keywords
diaminopirimidines
applications
new
same
compositions containing
Prior art date
Application number
UY0001032494A
Other languages
English (en)
Inventor
Stadtmueller Heinz
Kuhn Daniel
Sapountzis Ioannis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY32494A publication Critical patent/UY32494A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención comprende compuestos de la fórmula general /(1) en donde B, R1 a R5, Rx, m y n se definen como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por proliferación celular excesiva o anómala, así como su uso en tal tratamiento.
UY0001032494A 2009-03-18 2010-03-16 Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones UY32494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155515 2009-03-18
EP10153211 2010-02-10

Publications (1)

Publication Number Publication Date
UY32494A true UY32494A (es) 2010-10-29

Family

ID=42111169

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032494A UY32494A (es) 2009-03-18 2010-03-16 Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones

Country Status (17)

Country Link
US (2) US20110071158A1 (es)
EP (1) EP2408752B1 (es)
JP (1) JP5628281B2 (es)
KR (1) KR20110128927A (es)
CN (1) CN102421762A (es)
AR (1) AR076134A1 (es)
AU (1) AU2010224881A1 (es)
BR (1) BRPI1013618A2 (es)
CA (1) CA2755759A1 (es)
CL (1) CL2011002300A1 (es)
EA (1) EA201101330A1 (es)
IL (1) IL214746A0 (es)
MX (1) MX2011009780A (es)
TW (1) TW201043611A (es)
UY (1) UY32494A (es)
WO (1) WO2010106097A1 (es)
ZA (1) ZA201105986B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146981A2 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8412326B2 (en) * 2009-10-30 2013-04-02 Cardiac Pacemakers, Inc. Pacemaker with vagal surge monitoring and response
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
HUE046617T2 (hu) 2010-11-10 2020-03-30 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CA2890935A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN106146468B (zh) * 2015-04-17 2020-12-01 杭州雷索药业有限公司 吡啶酮类蛋白激酶抑制剂
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933680T2 (de) * 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
RS94703A (en) * 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP2090571B1 (de) * 2001-10-17 2012-05-16 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
EP1562935B1 (de) * 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE602004032446D1 (de) * 2003-08-07 2011-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
PE20080068A1 (es) * 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TWI432427B (zh) * 2006-10-23 2014-04-01 Cephalon Inc 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物

Also Published As

Publication number Publication date
MX2011009780A (es) 2011-09-30
AR076134A1 (es) 2011-05-18
CA2755759A1 (en) 2010-09-23
JP2012520850A (ja) 2012-09-10
US20140051674A1 (en) 2014-02-20
EP2408752B1 (en) 2015-08-12
KR20110128927A (ko) 2011-11-30
WO2010106097A1 (en) 2010-09-23
CN102421762A (zh) 2012-04-18
ZA201105986B (en) 2012-08-29
EP2408752A1 (en) 2012-01-25
BRPI1013618A2 (pt) 2016-04-19
JP5628281B2 (ja) 2014-11-19
EA201101330A1 (ru) 2012-04-30
IL214746A0 (en) 2011-11-30
TW201043611A (en) 2010-12-16
US20110071158A1 (en) 2011-03-24
CL2011002300A1 (es) 2012-01-20
AU2010224881A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY32259A (es) Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
UY33199A (es) 5-alquinil-pirimidinas.
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
ECSP11011558A (es) Nuevos compuestos químicos.
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CR20120264A (es) Compuestos
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112012029647A2 (pt) novos derivados de pirimidinas
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY32009A (es) 5-alquinil-pirimidinas
ECSP11010816A (es) Nuevos Compuestos
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
UY32748A (es) 2-carboxamida-cicloamino-ureas
CO6290768A2 (es) Tiazolil-dihidro-indazoles
CO6460762A2 (es) 5-alquinil-piridinas
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
ECSP12012110A (es) 5-alquinil-pirimidinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190123